Table 1.
Baseline characteristics of HBeAg-negative chronic HBV infection patients based on HBsAg levels.
| All (n = 392) | HBsAg <1000 IU/mL (n = 156) | HBsAg ≥1000 IU/mL (n = 236) | P value | |
|---|---|---|---|---|
| Age, years | 42 (36–51) | 44 (37–53) | 41 (35–49) | 0.0214 |
| Male, n (%) | 249 (63.5%) | 99 (63.5%) | 150 (63.6%) | 0.9843 |
| BMI | 23.4 (21.5–25.6) | 23.4 (21.7–25.2) | 23.2 (21.5–26.1) | 0.6318 |
| HBV family history, n (%) | 196 (50%) | 73 (46.8%) | 123 (52.1%) | 0.3021 |
| HCC family history, n (%) | 58 (14.8%) | 24 (15.4%) | 34 (14.4%) | 0.7896 |
| Leukocyte count (×109/L) | 5.4 (4.6–6.4) | 5.3 (4.7–6.2) | 5.5 (4.6–6.4) | 0.3255 |
| Platelet count (×109/L) | 177 (148–209) | 179 (148–211) | 174 (146–207) | 0.3151 |
| ALT, IU/L | 31 (22–43) | 28 (21–40) | 32 (23–44) | 0.0051 |
| ALT ≤ ULN, n (%) | 272 (69.4%) | 120 (76.9%) | 152 (64.4%) | 0.0085 |
| AST, IU/L | 27.5 (22.3–34) | 26 (22–32) | 28 (23–34) | 0.0267 |
| ALP, IU/L | 70 (57–82) (n = 381) | 69 (56–82) (n = 152) | 70 (58–84) (n = 229) | 0.2048 |
| GGT, IU/L | 20 (15–32) (n = 379) | 18 (14–26) (n = 152) | 23 (16–36) (n = 227) | 0.0014 |
| TB, µmol/L | 14.2 (11.4–18.6) | 14.7 (11.5–19.1) | 14.1 (11.1–18.5) | 0.3947 |
| HBV DNA, log100 IU/mL | 3.6 (2.9–4.5) | 3.4 (2.7–4.1) | 3.8 (3–4.9) | 0.0037 |
| HBsAg, log10 IU/mL | 3.2 (2.6–3.5) | 2.3 (1.7–2.7) | 3.4 (3.3–3.7) | <0.0001 |
| Necroinflammation ≥ G2, n (%) | 273 (69.4%) | 95 (60.9%) | 178 (75.4%) | 0.0022 |
| Fibrosis ≥ S2, n (%) | 241 (61.5%) | 85 (54.5%) | 156 (66.1%) | 0.0207 |
| Necroinflammation ≥ G2 or fibrosis ≥ S2, n (%) | 305 (77.8%) | 106 (67.9%) | 199 (84.3%) | 0.0001 |
ALT, alanine aminotransferase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; TB, total bilirubin abnormal.